Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial
Translational Stroke Research · 2026
DOI: 10.1007/s12975-025-01405-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Translational Stroke Research, 2026. Verfasst von Osvaldo J Laurido-Soto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Washington University School of Medicine (WUSM), 660 South Euclid Avenue, St. Louis, MO, 63110, USA. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Ischemic Stroke, Inflammation, Transcutaneous Electric Nerve Stimulation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Inflammation exacerbates brain injury following acute ischemic stroke (AIS). Transcutaneous auricular vagus nerve stimulation (taVNS) reduces systemic inflammation, but its efficacy in AIS remains unexplored. We examined the safety and anti-inflammatory effect of taVNS in AIS patients. Prospective Randomized Open-label blinded endpoint design, sham-controlled trial. Anterior circulation large vessel occlusion (LVO) AIS patients were assigned to twice-daily taVNS or sham stimulation for five days or until discharge. Inclusion criteria: age≥18 years, NIHSS≥6, anterior circulation LVO, and enrollment within 36-hours of last known normal (LKN). Primary endpoints were changes in inflammatory biomarkers (interleukins (IL)-1β, 6, 10, 17α, and tumor necrosis factor alpha (TNFα) on Days 0, 1, 3, 5, and 7). TaVNS safety endpoints included bradycardia, hypotension, infection, and death. Thirty-five patients (17 taVNS, 18 sham) were enrolled and taVNS/sham treatment started a mean of 0.99 days (SD 0.26 days) from LKN. Mean stimulations received were 8.24 (SD 2.77) and 7.33 (SD 3.20), for treatment vs. sham respectively. The rate of protocol adherence was 77%. TaVNS treatment significantly changed IL-6 levels compared to sham treatment (overall p=0.0001). Although overall trajectories of other cytokines did not significantly differ between groups, a post-hoc analysis found significant differences on day 3 cytokine levels between groups for: IL-1β (p=0.024), IL-6 (p=0.045), and IL-17α (p=0.044). No significant difference between treatment groups in safety endpoints were found. taVNS safely reduced post-AIS inflammation in anterior circulation LVO patients. These findings warrant further investigation in larger clinical trials.ClinicalTrials.gov ID: NCT05390580, https://clinicaltrials.gov/study/NCT05390580 -Study started/registered: September 26, 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Washington University School of Medicine (WUSM), 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
- Biomedical Engineering Department, 660 S. Euclid Avenue, Campus Box 1097, St. Louis, WU, 63130, USA.
- Neurology Department, Yale University School of Medicine, New Haven, CT, USA.
- Emergency Medicine Department, WUSM, STL, St. Louis, MO, USA.
- Neurology Department, Washington University School of Medicine (WUSM), 660 South Euclid Avenue, St. Louis, MO, 63110, USA. leejm@wustl.edu.
- Biomedical Engineering Department, 660 S. Euclid Avenue, Campus Box 1097, St. Louis, WU, 63130, USA. leejm@wustl.edu.
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
- Clinical and Translational Research Funding Program
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Laurido-Soto, O. J., Tan, G., Nielsen, S. S., Huguenard, A. L., Donovan, K. M., Xu, I., Giles, J., Dhar, R., Adeoye, O., Lee, J. M., & Leuthardt, E. (2026). Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. Translational Stroke Research. https://doi.org/10.1007/s12975-025-01405-6
Vancouver
Laurido-Soto OJ, Tan G, Nielsen SS, Huguenard AL, Donovan KM, Xu I, et al. Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. Translational Stroke Research. 2026. doi:10.1007/s12975-025-01405-6
BibTeX
@article{LauridoSoto2026,
author = {Laurido-Soto, Osvaldo J and Tan, Gansheng and Nielsen, Susan Searles and Huguenard, Anna L and Donovan, Kara M and Xu, Isabella and Giles, James and Dhar, Rajat and Adeoye, Opeolu and Lee, Jin-Moo and Leuthardt, Eric},
title = {Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial},
journal = {Translational Stroke Research},
year = {2026},
doi = {10.1007/s12975-025-01405-6}
}
EUVIMED